Managing treatment failure in pleural infection.

IF 2.7
Expert review of respiratory medicine Pub Date : 2026-04-01 Epub Date: 2025-12-08 DOI:10.1080/17476348.2025.2600106
Malvika Bhatnagar, Rebecca Burney, Eihab O Bedawi
{"title":"Managing treatment failure in pleural infection.","authors":"Malvika Bhatnagar, Rebecca Burney, Eihab O Bedawi","doi":"10.1080/17476348.2025.2600106","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Pleural infection is a common condition associated with significant morbidity, mortality, and prolonged hospital stay. Whilst antibiotics and chest tube drainage comprise initial management, over one-third of patients experience medical treatment failure, necessitating intrapleural enzyme therapy (IET) or surgery. This review examines advances in diagnosis and management of treatment failure in pleural infection.</p><p><strong>Areas covered: </strong>A literature search of PubMed, Embase, and Cochrane Library (January 2005- April 2025) was performed using keywords related to pleural infection, diagnostics, biomarkers, and treatment interventions. Treatment failure emerged as a multifactorial process involving delayed presentation, structural and physiological barriers such as increased pleural fluid viscosity, septation formation, pleural thickening, and biofilm development, alongside host factors and microbiological complexity. We review current strategies including antibiotics, chest tube drainage, IET (tPA + DNase), and surgical options, alongside emerging modalities such as next-generation sequencing, pleural biopsy, medical thoracoscopy, saline irrigation, and indwelling catheters.</p><p><strong>Expert opinion: </strong>Early identification of treatment failure within 48 hours is crucial for guiding escalation. A precision medicine approach integrating microbiological, radiological, and host-response data may redefine standards of care and improve outcomes. Future priorities include early risk stratification, biomarker-guided therapy, microbiome-informed antibiotic strategies, and improving global access to effective treatments.</p>","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"425-436"},"PeriodicalIF":2.7000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert review of respiratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17476348.2025.2600106","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/12/8 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Pleural infection is a common condition associated with significant morbidity, mortality, and prolonged hospital stay. Whilst antibiotics and chest tube drainage comprise initial management, over one-third of patients experience medical treatment failure, necessitating intrapleural enzyme therapy (IET) or surgery. This review examines advances in diagnosis and management of treatment failure in pleural infection.

Areas covered: A literature search of PubMed, Embase, and Cochrane Library (January 2005- April 2025) was performed using keywords related to pleural infection, diagnostics, biomarkers, and treatment interventions. Treatment failure emerged as a multifactorial process involving delayed presentation, structural and physiological barriers such as increased pleural fluid viscosity, septation formation, pleural thickening, and biofilm development, alongside host factors and microbiological complexity. We review current strategies including antibiotics, chest tube drainage, IET (tPA + DNase), and surgical options, alongside emerging modalities such as next-generation sequencing, pleural biopsy, medical thoracoscopy, saline irrigation, and indwelling catheters.

Expert opinion: Early identification of treatment failure within 48 hours is crucial for guiding escalation. A precision medicine approach integrating microbiological, radiological, and host-response data may redefine standards of care and improve outcomes. Future priorities include early risk stratification, biomarker-guided therapy, microbiome-informed antibiotic strategies, and improving global access to effective treatments.

胸膜感染治疗失败的处理。
简介:胸膜感染是一种常见的疾病,发病率、死亡率高,住院时间长。虽然抗生素和胸管引流是最初的治疗方法,但超过三分之一的患者经历药物治疗失败,需要胸膜内酶治疗(IET)或手术。本文综述了胸膜感染治疗失败的诊断和处理方面的进展。涉及领域:检索PubMed、Embase和Cochrane图书馆(2005年1月- 2025年4月)的文献,使用与胸膜感染、诊断、生物标志物和治疗干预相关的关键词。治疗失败是一个多因素的过程,包括延迟表现、结构和生理障碍,如胸膜液粘度增加、分隔形成、胸膜增厚、生物膜发育,以及宿主因素和微生物复杂性。我们回顾了目前的策略,包括抗生素、胸管引流、IET (tPA + DNase)和手术选择,以及新一代测序、胸膜活检、医学胸腔镜、盐水冲洗和留置导管等新兴方式。专家意见:48小时内早期识别治疗失败对于指导升级至关重要。整合微生物学、放射学和宿主反应数据的精准医学方法可能重新定义护理标准并改善结果。未来的优先事项包括早期风险分层、生物标志物引导治疗、微生物组信息抗生素策略,以及改善全球有效治疗的可及性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书